Ngā hua rapu - Baselga, Josè
- E whakaatu ana i te 1 - 20 hua o te 202
- Haere ki te Whārangi Whai Ake
-
1
-
2
Targeted therapies for breast cancer mā Higgins, Michaela J., Baselga, José
I whakaputaina 2011Text -
3
-
4
-
5
-
6
Implementing Genome-Driven Oncology mā Hyman, David M., Taylor, Barry S., Baselga, José
I whakaputaina 2017Text -
7
A view on drug resistance in cancer mā Vasan, Neil, Baselga, José, Hyman, David M.
I whakaputaina 2019Text -
8
-
9
-
10
-
11
-
12
The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein mā Borrell-Pagès, Maria, Fernández-Larrea, Juan, Borroto, Aldo, Rojo, Federico, Baselga, José, Arribas, Joaquín
I whakaputaina 2000Text -
13
Proteomic Identification of Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule as Substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis mā Bech-Serra, Joan J., Santiago-Josefat, Belén, Esselens, Cary, Saftig, Paul, Baselga, José, Arribas, Joaquín, Canals, Francesc
I whakaputaina 2006Text -
14
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation mā Anido, Judit, Scaltriti, Maurizio, Bech Serra, Joan Josep, Josefat, Belén Santiago, Rojo Todo, Federico, Baselga, José, Arribas, Joaquín
I whakaputaina 2006Text -
15
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance mā Wehrenberg-Klee, Eric, Turker, N. Selcan, Heidari, Pedram, Larimer, Benjamin, Juric, Dejan, Baselga, José, Scaltriti, Maurizio, Mahmood, Umar
I whakaputaina 2016Text -
16
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-cont... mā Miles, David, Baselga, José, Amadori, Dino, Sunpaweravong, Patrapim, Semiglazov, Vladimir, Knott, Adam, Clark, Emma, Ross, Graham, Swain, Sandra M.
I whakaputaina 2013Text -
17
Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial mā Bonner, James, Giralt, Jordi, Harari, Paul, Spencer, Sharon, Schulten, Jeltje, Hossain, Anwar, Chang, Shao-Chun, Chin, Steve, Baselga, José
I whakaputaina 2016Text -
18
TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS mā Raina, Deepak, Uchida, Yasumitsu, Kharbanda, Akriti, Rajabi, Hasan, Panchamoorthy, Govind, Jin, Caining, Kharbanda, Surender, Scaltriti, Maurizio, Baselga, Jose, Kufe, Donald
I whakaputaina 2013Text -
19
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer mā Prat, Aleix, Carey, Lisa A., Adamo, Barbara, Vidal, Maria, Tabernero, Josep, Cortés, Javier, Parker, Joel S., Perou, Charles M., Baselga, José
I whakaputaina 2014Text -
20
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors mā Jonas, Oliver, Landry, Heather M., Fuller, Jason E., Santini, John T., Baselga, Jose, Tepper, Robert I., Cima, Michael J., Langer, Robert
I whakaputaina 2015Text